Companies / Jade Biosciences, Inc.

Jade Biosciences, Inc.

Nasdaq: JBIOCIK 1798749WALTHAM, MA

Financials

Revenue—
Net income$-127.41M
Total debt—
Cash$107.25M
Diluted EPS$-3.19
Shares outstanding63.6M

Ownership

63.6M shares outstanding · as of Aug 3, 2026
0.85%Insiders
Ownership
Insiders0.85%538,382
10%+ / strategic8.55%5,436,870
Institutions73.56%46,783,703
Public float17.04%10,838,432

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 5

View all →
Insider% of sharesShares
King Andrew JamesSee Remarks
0.61%386,113
Frohlich TomCEOChief Executive Officer · Director
0.14%86,331
Dahms Bradford D.Chief Financial Officer
0.06%37,813
Balta ElizabethSee Remarks
0.04%28,125
Dobmeier EricDirector
——

Institutional holders 109

View all →
HolderValue% of shares
Fmr LLC$106.38M10.84%
Fairmount Funds Management LLC$70.26M7.16%
BlackRock, Inc.$62.25M4.40%
State Street Corporation$51.89M3.67%
RA Capital Management, L.P.$51.58M5.77%
Bellevue Group AG$51.55M5.25%
VR Adviser, LLC$49.69M5.06%
Janus Henderson Group PLC$43.56M4.88%
Remedium Capital Partners, LLC$35.06M2.48%
Vanguard Group Inc$32.34M3.30%

Activity

View all →
InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Feb 12, 2026Frohlich Tom
CEO
GrantCommon Stock$0+79K
+1038.78%
86,331
0.14% of shares
low
Feb 12, 2026King Andrew James
Executive
GrantCommon Stock$0+41K
+11.96%
386,113
0.61% of shares
low
Feb 12, 2026Dahms Bradford D.
Executive
GrantCommon Stock$0+38K
37,813
0.06% of shares
low
Feb 12, 2026Balta Elizabeth
Executive
GrantCommon Stock$0+28K
28,125
0.04% of shares
low
Jun 9, 2026Dobmeier Eric
Director
GrantStock Option (Right to Buy)—+35K
34,843
0.05% of shares
low
Feb 12, 2026Frohlich Tom
CEO
GrantStock Option (Right to Buy)—+473K
472,500
0.74% of shares
low
Feb 12, 2026King Andrew James
Executive
GrantStock Option (Right to Buy)—+248K
247,500
0.39% of shares
low
Feb 12, 2026Dahms Bradford D.
Executive
GrantStock Option (Right to Buy)—+227K
226,875
0.36% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A—2,095,767—
Janus Henderson Group PLCPassive13G———
Bellevue Group AGPassive13G—3,341,103—
Venrock Healthcare Capital Partners III, L.P.Passive13G/A———
Deep Track Capital, LPPassive13G/A—0—
Janus Henderson Group PLCPassive13G/A———

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
JBIO——008064206—